2 news items
Soleno Therapeutics Announces Pricing of Approximately $138 Million Public Offering Of Common Stock
SLNO
2 May 24
its lead candidate, DCCR tablets for the treatment of Prader-Willi Syndrome (PWS), and to provide for general corporate purposes, which may include
Soleno Therapeutics Announces Proposed Public Offering of Common Stock
SLNO
2 May 24
for general corporate purposes, which may include working capital, capital expenditures, other clinical trials, other corporate expenses and acquisitions
- Prev
- 1
- Next